Single dose of Johnson & Johnson COVID-19 vaccine candidate demonstrates robust protection in pre-clinical studies

Johnson & JohnsonJohnson & Johnson (NYSE: JNJ) (the Company) today announced that its lead vaccine candidate protected against infection with SARS-CoV-2, the virus that causes COVID-19, in pre-clinical studies. The data, published in Nature, show the Company's investigational adenovirus serotype 26 (Ad26) vector-based vaccine elicited a robust immune response as demonstrated by "neutralizing antibodies," successfully preventing subsequent infection and providing complete or near-complete protection in the lungs from the virus in non-human primates (NHPs) in the pre-clinical study.


from Breaking World Pharma News https://ift.tt/2EC4knd

Comments